

## Prof. MUSTAFA ERMAN

### Personal Information

Office Phone: [+90 312 305 3432](tel:+903123053432)

Office Phone: [+90 312 305 4330](tel:+903123054330)

Fax Phone: [+90 312 305 4312](tel:+903123054312)

Email: [ermanm@hacettepe.edu.tr](mailto:ermanm@hacettepe.edu.tr)

Other Email: [ermanm1968@gmail.com](mailto:ermanm1968@gmail.com)

Web: <https://avesis.hacettepe.edu.tr/ermanm>

Address: Hacettepe Üniversitesi Onkoloji Hastanesi Prevanatif Onkoloji AD Sıhhiye 06100 Ankara

### Education Information

Post Doctorate of Medicine, Hacettepe University, Medikal Onkoloji, Turkey 1998 - 2001

Expertise In Medicine, Hacettepe University, İç Hastalıkları, Turkey 1992 - 1997

Undergraduate, Hacettepe University, Tıp, Turkey 1986 - 1992

### Foreign Languages

English, C2 Mastery

French, C1 Advanced

### Research Areas

Medicine, Health Sciences, Internal Medicine Sciences, Internal Diseases , Oncology

### Academic Titles / Tasks

Professor, Hacettepe University, Kanser Enstitüsü, Prevanatif Ve Onkoloji Anabilim Dalı, 2016 - Continues

Associate Professor, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2006 - 2016

Assistant Professor, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2005 - 2006

Lecturer PhD, Hacettepe University, Tıp Fakültesi (İngilizce), Dahili Tıp Bilimleri Bölümü, 2001 - 2005

### Academic and Administrative Experience

Assistant Director of the Institute, Hacettepe University, Kanser Enstitüsü, 2019 - Continues

Hacettepe Üniversitesi, Hacettepe Üniversitesi Klinik Araştırmalar Uygulama Ve Araştırma Merkezi (Hükam), 2017 - Continues

### Published journal articles indexed by SCI, SSCI, and AHCI

- I. Adrenocortical Cancer in the Real World: A Comprehensive Analysis of Clinical Features and

## **Management from the Turkish Oncology Group (TOG)**

YAŞAR H. A., AKTAŞ B. Y., Ucar G., SEZGİN GÖKSU S., Bilgetekin I., Cakar B., Sakin A., Ates O., Basoglu T., Arslan C., et al.

Clinical Genitourinary Cancer, vol.22, no.3, 2024 (SCI-Expanded)

- II. **The efficacy of immunotherapy and chemoimmunotherapy in patients with advanced rare tumors: A Turkish oncology group (TOG) study**  
Güven D. C., Aykan M. B., MUĞLU H., BAYRAM E., Helvacı K., DURSUN B., Celayir M., Chelebiyev E., Nayir E., ERMAN M., et al.  
Cancer Medicine, vol.13, no.1, 2024 (SCI-Expanded)
- III. **Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?**  
GÜNER G., AKTAŞ B. Y., Başal F. B., DEMİRKAZIK A., Gürsoy P., Demirci U., ERMAN M., Yumuk P. F., Şenler F. Ç., Cakar B., et al.  
Journal of Cancer Research and Clinical Oncology, vol.149, no.14, pp.13271-13277, 2023 (SCI-Expanded)
- IV. **The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., KAVGACI G., Aksun M. S., ERUL E., YILDIRIM H. Ç., Chalabiyev E., Cebroyilov C., YILDIRIM T., et al.  
Anti-Cancer Drugs, vol.34, no.6, pp.783-790, 2023 (SCI-Expanded)
- V. **The benefit of treatment beyond progression with immune checkpoint inhibitors: a multi-center retrospective cohort study**  
GÜVEN D. C., Yekeduz E., Erul E., YAZGAN S. C., ŞAHİN T. K., KARATAŞ G., AKSOY S., ERMAN M., YALÇIN Ş., ÜRÜN Y., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.149, no.7, pp.3599-3606, 2023 (SCI-Expanded)
- VI. **Five-Year Outcome and Safety in Patients Treated With Immune Checkpoint Blockade Therapies for Urothelial Carcinoma: Experience From Real-World Clinical Practice**  
Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Akar E., ERMAN M., ÜRÜN Y., Erdem D., Karadurmus N., Kilickap S.  
Clinical Genitourinary Cancer, vol.21, no.3, pp.334-341, 2023 (SCI-Expanded)
- VII. **Immunogenicity of two doses of inactive COVID-19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy**  
GÜVEN D. C., Incesu F. G. G., YILDIRIM H. Ç., Erul E., Chalabiyev E., AKTAŞ B. Y., YÜCE D., ARIK Z., KILIÇKAP S., AKSOY S., et al.  
INTERNATIONAL JOURNAL OF CANCER, vol.152, pp.679-685, 2023 (SCI-Expanded)
- VIII. **NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC**  
de Castro G., Rizvi N. A., Schmid P., Syrigos K., Martin C., Yamamoto N., Cheng Y., Moiseyenko V., Summers Y., Vynnychenko I., et al.  
Journal of Thoracic Oncology, vol.18, no.1, pp.106-119, 2023 (SCI-Expanded)
- IX. **Blood Based Biomarkers as Predictive Factors for Hyperprogressive Disease**  
YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKSOY S., ERMAN M., Kilickap S., YALÇIN Ş.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.17, 2022 (SCI-Expanded)
- X. **The Association between Early Changes in Neutrophil-Lymphocyte Ratio and Survival in Patients Treated with Immunotherapy**  
GÜVEN D. C., ŞAHİN T. K., Erul E., ÇAKIR İ. Y., ÜÇGÜL E., YILDIRIM H. Ç., AKTEPE O. H., ERMAN M., KILIÇKAP S., AKSOY S., et al.  
JOURNAL OF CLINICAL MEDICINE, vol.11, no.15, 2022 (SCI-Expanded)
- XI. **Effect of docetaxel (D) use on survival outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC) treated with novel hormonal therapies (NHTs): A meta-analysis.**  
Güven D. C., Sayegh N., Tripathi N., Erman M., Agarwal N., Swami U.  
JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.16, 2022 (SCI-Expanded)

- XII. **The burden of polypharmacy and drug-drug interactions in older cancer patients treated with immunotherapy**  
 GÜVEN D. C., KAVGACI G., AKTEPE O. H., YILDIRIM H. H., ŞAHİN T. K., AKSOY S., ERMAN M., KILIÇKAP S., YALÇIN Ş.  
 JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.28, no.4, pp.785-793, 2022 (SCI-Expanded)
- XIII. **Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO)**  
 Levy B., Barlesi F., Paz-Ares L., Bennouna J., ERMAN M., Felip E., Isla D., Kim H. R., Kim S., Madelaine J., et al.  
 LUNG CANCER, vol.166, pp.107-113, 2022 (SCI-Expanded)
- XIV. **Response to first-line chemotherapy regimen is associated with efficacy of immune checkpoint blockade therapies in patients with metastatic urothelial carcinoma**  
 Tural D., Selcukbiricik F., Olmez O. F., Sumbul A. T., ERMAN M., COŞKUN H. Ş., ARTAÇ M., Kilickap S.  
 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.27, no.3, pp.585-591, 2022 (SCI-Expanded)
- XV. **Long-term outcome and safety in patients treated with immune checkpoint blockade therapies for urothelial carcinoma: Experience from real-world clinical practice.**  
 Tural D., Arslan C., Selcukbiricik F., Olmez O. F., Erman M., Urun Y., Karadurmus N., Akar E., Kilickap S.  
 JOURNAL OF CLINICAL ONCOLOGY, vol.40, no.6, 2022 (SCI-Expanded)
- XVI. **The association between antibiotic use and survival in renal cell carcinoma patients treated with immunotherapy: a multi-center study**  
 GÜVEN D. C., Acar R., Yekeduz E., Bilgetekin I., Baytemur N. K., EROL C., Ceylan F., ŞENDUR M. A. N., Demirci U., ÜRÜN Y., et al.  
 CURRENT PROBLEMS IN CANCER, vol.45, no.6, 2021 (SCI-Expanded)
- XVII. **The Predictive Value of Red Blood Cell Distribution Width for Survival Outcomes of Metastatic Renal Cell Carcinoma Patients Treated with Targeted Therapy**  
 AKTEPE O. H., GÜVEN D. C., ŞAHİN T. K., YILDIRIM H. Ç., ÇELİKTEKİN B., Yeter H. H., YÜCE D., DİZDAR Ö., ERMAN M.  
 NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, vol.73, no.10, pp.1957-1963, 2021 (SCI-Expanded)
- XVIII. **Should Protocols Specific to Histologic Subtypes Be Applied in the Follow-Up of NSCLC?**  
 ARIK Z., ERMAN M.  
 JOURNAL OF THORACIC ONCOLOGY, vol.16, no.10, 2021 (SCI-Expanded)
- XIX. **Lower prognostic nutritional index is associated with poorer survival in patients receiving immune-checkpoint inhibitors**  
 GÜVEN D. C., AKTEPE O. H., TABAN H., AKTAŞ B. Y., GÜNER G., YILDIRIM H. H., ŞAHİN T. K., AKSUN M. S., DİZDAR Ö., AKSOY S., et al.  
 BIOMARKERS IN MEDICINE, vol.15, no.13, pp.1123-1130, 2021 (SCI-Expanded)
- XX. **Poorer baseline performance status is associated with increased thromboembolism risk in metastatic cancer patients treated with immunotherapy**  
 GÜVEN D. C., AKSUN M. S., ŞAHİN T. K., AKTEPE O. H., YILDIRIM H. Ç., TABAN H., Ceylan F., KERTMEN N., ARIK Z., DİZDAR Ö., et al.  
 SUPPORTIVE CARE IN CANCER, vol.29, no.9, pp.5417-5423, 2021 (SCI-Expanded)
- XXI. **Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences**  
 Tural D., Olmez O. F., Sumbul A. T., ARTAÇ M., Ozhan N., Akar E., ÇAKAR B., Kostek O., Ekenel M., ERMAN M., et al.  
 EUROPEAN UROLOGY FOCUS, vol.7, no.5, pp.1061-1066, 2021 (SCI-Expanded)
- XXII. **Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study**  
 Blackhall F., Jao K., Greillier L., Cho B. C., Penkov K., Reguart N., Majem M., Nackaerts K., Syrigos K., Hansen K., et al.  
 JOURNAL OF THORACIC ONCOLOGY, vol.16, no.9, pp.1547-1558, 2021 (SCI-Expanded)
- XXIII. **Prognostic factors in patients with metastatic urothelial carcinoma who have treated with Atezolizumab**  
 Tural D., Olmez O. F., Sumbul A. T., Ozhan N., ÇAKAR B., Kostek O., Ekenel M., ERMAN M., COŞKUN H. Ş., Selcukbiricik F., et al.  
 INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, vol.26, pp.1506-1513, 2021 (SCI-Expanded)

- XXIV. **THE INCIDENCE AND RISK FACTORS FOR ACUTE KIDNEY INJURY IN PATIENTS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: A REAL-LIFE STUDY**  
GÜVEN D. C., ÖZBEK D. A., ŞAHİN T. K., AKSUN M. S., KAVGACI G., Cebrayilov C., YILDIRIM T., DİZDAR Ö., AKSOY S., KILIÇKAP S., et al.  
NEPHROLOGY DIALYSIS TRANSPLANTATION, vol.36, 2021 (SCI-Expanded)
- XXV. **Evaluation of emergency departments visits in patients treated with immune checkpoint inhibitors**  
GÜVEN D. C., ŞAHİN T. K., AKSUN M. S., TABAN H., AKTEPE O. H., METİN AKSU N., AKKAŞ M., ERMAN M., KILIÇKAP S., DİZDAR Ö., et al.  
SUPPORTIVE CARE IN CANCER, vol.29, no.4, pp.2029-2035, 2021 (SCI-Expanded)
- XXVI. **Association of response to first-line chemotherapy with the efficacy of atezolizumab in patients with metastatic urothelial carcinoma.**  
Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., Cakar B., Kostek O., Ekenel M., COŞKUN H. Ş., et al.  
JOURNAL OF CLINICAL ONCOLOGY, vol.39, no.6, 2021 (SCI-Expanded)
- XXVII. **Survival Outcomes of Patients in Advanced Non-Clear Renal Cell Carcinoma Treated with Pazopanib: A Retrospective Single Institution Experience**  
AKTEPE O. H., ERMAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.31, no.3, pp.170-177, 2021 (SCI-Expanded)
- XXVIII. **GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients**  
Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., Demirci U., Christopoulos P., ÇİÇİN İ., Basal F. B., et al.  
LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded)
- XXIX. **Pembrolizumab- and/or pazopanib-induced remitting seronegative symmetrical synovitis with pitting edema in a patient with renal cell carcinoma**  
BAŞ O., Ozbek A., Guven D., Aktepe O., KILIÇ L., KERTMEN N., ERMAN M.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.5, pp.1230-1233, 2020 (SCI-Expanded)
- XXX. **Drug-related problems with targeted/immunotherapies at an oncology outpatient clinic**  
Kucuk E., EKİNCİOĞLU A., ERMAN M., KILIÇKAP S.  
JOURNAL OF ONCOLOGY PHARMACY PRACTICE, vol.26, no.3, pp.595-602, 2020 (SCI-Expanded)
- XXXI. **Electrophysiologic evaluation of facial nerve functions after oxaliplatin treatment**  
Yiğit Ö., Kulak Kayıkcı M. E., Temuçin Ç. M., Sarac S., Erman M., Belgin E.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.84, no.3, pp.513-520, 2019 (SCI-Expanded)
- XXXII. **Short-time use of crizotinib as neoadjuvant in ALK-positive non-small cell lung carcinoma can be a chance for resectability**  
KILIÇKAP S., Onder S., DİZDAR Ö., ERMAN M., ÜNER A.  
CANCER CHEMOTHERAPY AND PHARMACOLOGY, vol.83, no.6, pp.1195-1196, 2019 (SCI-Expanded)
- XXXIII. **Afatinib With Pembrolizumab for Treatment of Patients With Locally Advanced/Metastatic Squamous Cell Carcinoma of the Lung: The LUX-Lung IO/KEYNOTE 497 Study Protocol**  
Levy B., Paz-Ares L., Bennouna J., Felip E., Rodriguez Abreu D., Isla D., Barlesi F., Molinier O., Madelaine J., Audigier-Valette C., et al.  
CLINICAL LUNG CANCER, vol.20, no.3, 2019 (SCI-Expanded)
- XXXIV. **Middle East observational study in metastatic soft tissue sarcoma: an epidemiological study on the treatment patterns (MOON)**  
Memon M. A., Karaca B., Aboelhassan R., Barsoum M., ERMAN M., Basaran M., Sevinc A., Hanene D., Slader C., Pilipovic V., et al.  
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.144, no.11, pp.2219-2229, 2018 (SCI-Expanded)
- XXXV. **Factors associated with quitting action following smoking cessation counseling.**  
Hayran K. M., Yuce D., Erman M., Dizdar O., Kilickap S., HUSEYİN B.  
JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)
- XXXVI. **Afatinib in combination with pembrolizumab in patients (pts) with stage IIIB/IV squamous cell carcinoma (SCC) of the lung**

Levy B. P., Paz-Ares L. G., Bennouna J., Felip E., Abreu D. R., Isla D., Barlesi F., Molinier O., Madelaine J., Audigier-Valette C., et al.

JOURNAL OF CLINICAL ONCOLOGY, vol.36, no.15, 2018 (SCI-Expanded)

- XXXVII. **Clinical Pharmacy Practices in Oncology Patients Treated with Tyrosine Kinase Inhibitors**  
Tecen-Yucel K., Bayraktar-Ekincioglu A., KILIÇKAP S., ERMAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.28, no.1, pp.53-60, 2018 (SCI-Expanded)
- XXXVIII. **Survival following laparoscopic adrenalectomy for solitary metastasis of lung cancer**  
Tonyali S., HABERAL H. B., Yazici S., ERMAN M., KAYNAROĞLU Z. V., BİLEN C. Y.  
INTERNATIONAL UROLOGY AND NEPHROLOGY, vol.48, no.11, pp.1803-1809, 2016 (SCI-Expanded)
- XXXIX. **Vaccination perception and attitudes among patients with cancer receiving chemotherapy**  
AKIN Ş., DİZDAR Ö., Karakas Y., ÖZİŞİK L., Tanriover M. D., Kamisli S., ERMAN M., HAYRAN K. M.  
ANNALS OF ONCOLOGY, vol.27, 2016 (SCI-Expanded)
- XL. **Renal cell cancer: overview of the current therapeutic landscape**  
ERMAN M., Benekli M., Basaran M., BAVBEK S., Buyukberber S., Coskun U., DEMİR G., KARABULUT B., OKSUZOĞLU B., ÖZKAN M., et al.  
EXPERT REVIEW OF ANTICANCER THERAPY, vol.16, no.9, pp.955-968, 2016 (SCI-Expanded)
- XLI. **Effect of Zoledronic Acid on Rats' Tissue SDF-1 Expression**  
Arik Z., KILIÇKAP S., AKPULAT U., Nahit Sendur M. A., KOCAEFE Y. Ç., ERMAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.4, pp.215-219, 2016 (SCI-Expanded)
- XLII. **Vaccination Attitudes Among Patients with Cancer Receiving Chemotherapy**  
AKIN S., DİZDAR Ö., ÖZİŞİK L., TANRIOVER M., KAMISLI S., ERMAN M., HAYRAN M.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.26, no.3, pp.167-172, 2016 (SCI-Expanded)
- XLIII. **QUALITY OF LIFE DOMAINS ASSOCIATED WITH READMISSION**  
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., ÇELİK İ.  
VALUE IN HEALTH, vol.18, no.3, 2015 (SCI-Expanded)
- XLIV. **Nationwide Smoking Cessation Treatment Support Program - Turkey project**  
ÇELİK İ., YÜCE D., Hayran M., ERMAN M., KILIÇKAP S., BUZĞAN T., Irmak H., TOSUN N., Tuncer M., AKDAĞ R.  
HEALTH POLICY, vol.119, no.1, pp.50-56, 2015 (SCI-Expanded)
- XLV. **HEALTH RELATED QUALITY OF LIFE IN CANCER PATIENTS: EVALUATION WITH A SELF-ADMINISTERED IPAD APPLICATION**  
YÜCE D., HAYRAN K. M., KILIÇKAP S., ERMAN M., ÇELİK İ.  
VALUE IN HEALTH, vol.17, no.7, 2014 (SCI-Expanded)
- XLVI. **ASSOCIATION OF HEALTH CARE COST WITH QUALITY OF LIFE FOR VARIOUS TYPES OF CANCERS**  
HAYRAN K. M., YÜCE D., Huseyin B., Esin E., KILIÇKAP S., ERMAN M., ÇELİK İ.  
VALUE IN HEALTH, vol.17, no.7, 2014 (SCI-Expanded)
- XLVII. **Aromatase Inhibitors and Safety: Clinical or Statistical Significance?**  
Esin E., YÜCE D., KILIÇKAP S., ERMAN M.  
JOURNAL OF CLINICAL ONCOLOGY, vol.31, no.27, pp.3439, 2013 (SCI-Expanded)
- XLVIII. **Effect of Endocrine Therapy on Quality of Life and Cognitive Functions in Patients with Breast Cancer**  
KILIÇKAP S., HAYRAN M., ÇAKIR B., ÇİLİNGİROĞLU N., ERMAN M., Buyukdamgaci G., OZISIK Y.  
BREAST CARE, vol.8, no.2, pp.128-132, 2013 (SCI-Expanded)
- XLIX. **Pituitary Gland Metastasis of Breast Cancer: A Case Report**  
Ozkan C., ARSLAN Ç., KILIÇ M., ERMAN M., Altundag K.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.22, no.1, pp.42-45, 2012 (SCI-Expanded)
- L. **Isolated Bone Metastases in Early Stage Endometrial Adenocarcinoma: A Case Report and Review of the Literature**  
Kurt M., KILIÇKAP S., AKSOY S., ERMAN M., Gedikoglu G., Turker A.  
UHOD-ULUSLARARASI HEMATOLOJİ-ONKOLOJİ DERGİSİ, vol.21, no.1, pp.52-56, 2011 (SCI-Expanded)
- LI. **FREQUENCY OF CANCER TYPES IN PATIENTS AGED 65 AND OLDER: RESULTS FROM CANCER REGISTRY DATABASE OF HACETTEPE UNIVERSITY HOSPITALS**

Arslan C., KILIÇKAP S., Dede D. S., HAYRAN K. M., ERMAN M., ÇELİK İ., Kutluk T.

TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, vol.14, no.3, pp.187-192, 2011 (SCI-Expanded)

- LII. **Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma**  
KILIÇKAP S., Yavuz B., AKSOY S., Sahiner L., DİNÇER M., HARPUTLUOĞLU H., ERMAN M., AYTEMİR K., Tokgozoglul., BARIŞTA İ.  
MEDICAL ONCOLOGY, vol.25, no.4, pp.437-442, 2008 (SCI-Expanded)
- LIII. **Platelet size has diagnostic predictive value for bone marrow metastasis in patients with solid tumors**  
AKSOY S., KILIÇKAP S., Hayran M., HARPUTLUOĞLU H., KOCA E., Dede D. S., ERMAN M., TÜRKER A.  
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, vol.30, no.3, pp.214-219, 2008 (SCI-Expanded)
- LIV. **Erectile dysfunction in successfully treated lymphoma patients**  
AKSOY S., HARPUTLUOĞLU H., KILIÇKAP S., DİNÇER M., DİZDAR Ö., AKDOĞAN B., Ozen H., ERMAN M., ÇELİK İ.  
SUPPORTIVE CARE IN CANCER, vol.16, no.3, pp.291-297, 2008 (SCI-Expanded)
- LV. **A decision-analytic model for early stage breast cancer: Lumpectomy vs mastectomy**  
Alogan G. B., Elele T., Hayran M., ERMAN M., KILIÇKAP S.  
NEOPLASMA, vol.55, no.3, pp.222-228, 2008 (SCI-Expanded)
- LVI. **Vascular endothelial growth factor, vascular endothelial growth factor receptor-3 and cyclooxygenase-2 expression in psoriasis**  
YALÇIN B., Tezel G. G., ARDA N., ERMAN M., ALLI N.  
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, vol.29, no.6, pp.358-364, 2007 (SCI-Expanded)
- LVII. **Molecular mechanisms of signal transduction: Epidermal growth factor receptor family, Vascular endothelial growth factor family, Kit, Platelet-derived growth factor receptor, Ras**  
Erman M.  
JOURNAL OF BUON, vol.12, 2007 (SCI-Expanded)
- LVIII. **Thymic epithelial neoplasia - A study of 58 cases**  
ELKIRAN E. T., Abali H., Aksoy S., Altundag K., Erman M., Kars A., Turker A., TEKUZMAN G., Ozisik Y.  
MEDICAL ONCOLOGY, vol.24, no.2, pp.197-201, 2007 (SCI-Expanded)
- LIX. **Pneumocystis carinii pneumonia in a rheumatoid arthritis patient treated with adalimumab**  
Kalyoncu U., Karadag O., Akdogan A., KISACIK B., Erman M., Erguven S., Ertenli A. I.  
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, vol.39, no.5, pp.475-478, 2007 (SCI-Expanded)
- LX. **Expressions of vascular endothelial growth factor and CD34 in oral aphthous lesions of Behcet's disease**  
YALÇIN B., ARDA N., Tezel G. G., ERMAN M., ALLI N.  
ANALYTICAL AND QUANTITATIVE CYTOLOGY AND HISTOLOGY, vol.28, no.6, pp.303-306, 2006 (SCI-Expanded)
- LXI. **Extensive exfoliative dermatitis induced by chlorambucil**  
Kilickap S., Kurt M., Aksoy S., Erman M., Turker A.  
AMERICAN JOURNAL OF HEMATOLOGY, vol.81, no.11, pp.891-892, 2006 (SCI-Expanded)
- LXII. **Accelerated hepatitis C virus replication with rituximab treatment in a non-Hodgkin's lymphoma patient**  
Aksoy S., Abali H., Kilickap S., Erman M., Kars A.  
CLINICAL AND LABORATORY HAEMATOLOGY, vol.28, no.3, pp.211-214, 2006 (SCI-Expanded)
- LXIII. **Lithium-associated hypothyroidism and thyroid papillary carcinoma: A case report**  
Aksoy S., Kilickap S., Erman M.  
SOUTHERN MEDICAL JOURNAL, vol.99, no.3, pp.279-281, 2006 (SCI-Expanded)
- LXIV. **Nasopharynx carcinoma complicated with pneumocephalus**  
Dizdar O., Kilickap S., Aksoy S., Cizginer S., Erman M.  
JOURNAL OF NEURO-ONCOLOGY, vol.77, no.1, pp.107-108, 2006 (SCI-Expanded)
- LXV. **Nonconvulsive status epilepticus due to ifosfamide**  
Kilickap S., ÇAKAR M., Onal I., Tufan A., Akoglu H., Aksoy S., Erman M., TEKUZMAN G.  
ANNALS OF PHARMACOTHERAPY, vol.40, no.2, pp.332-335, 2006 (SCI-Expanded)

- LXVI. **Metastatic granular cell tumor: A case report and review of the literature**  
Aksoy S., Abali H., Kilickap S., HARPUTLUOĞLU H., Erman M.  
ACTA ONCOLOGICA, vol.45, no.1, pp.91-94, 2006 (SCI-Expanded)
- LXVII. **Multivariate analysis of factors predictive of brain metastases in localised non-small cell lung carcinoma**  
Kilickap S., Aksoy S., Erman M.  
LUNG CANCER, vol.49, no.1, pp.129, 2005 (SCI-Expanded)
- LXVIII. **Ovarian carcinoma in two patients with chronic liver disease**  
Isildak M., SAİN GÜVEN G., Kekilli M., Beyazit Y., ERMAN M.  
WORLD JOURNAL OF GASTROENTEROLOGY, vol.11, no.28, pp.4445-4446, 2005 (SCI-Expanded)
- LXIX. **Fludarabine phosphate may be useful in the treatment of graft-versus-host disease**  
Aksoy S., Abali H., Kilickap S., DİNÇER M., Erman M.  
MEDICAL HYPOTHESES, vol.64, no.6, pp.1150-1152, 2005 (SCI-Expanded)
- LXX. **Tamoxifen-induced tissue factor pathway inhibitor reduction: a clue for an acquired thrombophilic state?**  
Erman M., Abali H., ORAN B., Haznedaroglu I., Canpinar H., KIRAZLI Ş., Celik I.  
ANNALS OF ONCOLOGY, vol.15, no.11, pp.1622-1626, 2004 (SCI-Expanded)
- LXXI. **Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in Turkish women - A case-control study**  
ORAN B., Celik I., Erman M., BALTALI E., ZENGİN N., Demirkazik F., TEZCAN S.  
MEDICAL ONCOLOGY, vol.21, no.1, pp.31-39, 2004 (SCI-Expanded)
- LXXII. **Coincidental detection of T-cell rich B cell lymphoma in the para-aortic lymph nodes of a woman undergoing lymph node dissection for cervical cancer: A case report**  
Abali H., Eren O. Ö., Erman M., Uner A., Kose F., GÜLER N.  
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, vol.13, no.5, pp.687-689, 2003 (SCI-Expanded)
- LXXIII. **Concomitant Mycobacterium tuberculosis and Aspergillus niger infection in a patient with acute myeloid leukemia**  
AKSOY D., TURKER A., ALTUNDAG M. K., ABALI H., DURUSU M., ERMAN M., UNER A., SUNGUR A., Unal S., UZUN O.  
CHEMOTHERAPY, vol.49, no.5, pp.264-266, 2003 (SCI-Expanded)
- LXXIV. **Correlation of in vitro fluconazole susceptibility with clinical outcome for severely ill patients with oropharyngeal candidiasis**  
ARIKAN S., AKOVA M., HAYRAN M., OZDEMİR O., ERMAN M., GUR D., Unal S.  
CLINICAL INFECTIOUS DISEASES, vol.26, no.4, pp.903-908, 1998 (SCI-Expanded)
- LXXV. **A randomized multicenter comparative study of cefepime and ceftazidime in combination with amikacin in the treatment of patients with fever and neutropenia**  
ERMAN M., Akan H., KORTEN V., Ferhanoglu B., UZUN Ö., ÜNAL S., AKOVA M.  
Clinical Infectious Diseases, vol.25, no.2, pp.463, 1997 (SCI-Expanded)

## Articles Published in Other Journals

- I. **Mean Platelet Volume to Lymphocyte Ratio: A New Biomarker Predicting Response in Patients with Solid Tumors Treated with Nivolumab**  
YILDIRIM H. Ç., KUŞ F., GÜVEN D. C., Karaca E., KAYGUSUZ Y., DİZDAR Ö., AKSOY S., ERMAN M., YALÇIN Ş., Kilickap S.  
Journal of Immunotherapy and Precision Oncology, vol.6, no.4, pp.170-176, 2023 (Scopus)
- II. **Everolimus and/or Nivolumab-Associated Cytomegalovirus Colitis in a Patient with Metastatic Renal Cell Carcinoma**  
Ismayilov R., AKTEPE O. H., Sardarova K., LEBLEBİCİ C. B., ERMAN M.  
EURASIAN JOURNAL OF MEDICINE, vol.54, no.1, pp.77-79, 2022 (ESCI)
- III. **Differences between Hyperprogressive Disease and Progressive Disease in Patients Receiving Immunotherapy**

YILDIRIM H. Ç., GÜVEN D. C., AKTEPE O. H., TABAN H., YILMAZ F., YAŞAR S., AKTAŞ B. Y., GÜNER G., DİZDAR Ö., AKSOY S., et al.

EURASIAN JOURNAL OF MEDICINE AND ONCOLOGY, vol.6, no.1, pp.59-63, 2022 (ESCI)

**IV. Does Combined Fractionated Stereotactic Radiotherapy and Immunotherapy Change the Outcome of Recurrent High-Grade Gliomas?**

Sari S. Y., AKTAŞ B. Y., KERTMEN N., ELMALI A., Kilickap S., Oguz K. K., MUT AŞKUN M., ERMAN M., Soylemezoglu F., Zorlu F., et al.

CUREUS, vol.13, no.6, 2021 (ESCI)

**V. Impact of albumin to globulin ratio on survival outcomes of patients with metastatic renal cell carcinoma**

AKTEPE O. H., GÜNER G., GÜVEN D. C., TABAN H., YILDIRIM H. Ç., ŞAHİN T. K., Ardic F. S., Yeter H. H., YÜCE D., ERMAN M.

TURKISH JOURNAL OF UROLOGY, vol.47, no.2, pp.113-119, 2021 (ESCI)

**VI. BİR SİGARA BIRAKMA POLİKLİNİĞİNDE UYGULANAN PSİKOEĞİTİMSEL SİGARA BIRAKMA POROGRAMININ ETKİNLİĞİ**

KAMIŞLI S., YÜCE D., küçükçoban ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., ERMAN M.

Anadolu Hemşirelik ve Sağlık Bilimleri Dergisi, vol.20, no.4, pp.234-242, 2017 (Peer-Reviewed Journal)

## Books & Book Chapters

**I. Kastrasyona dirençli prostat kanseri tedavisi**

ERMAN M., ARIK Z.

in: Üroonkoloji Kitabı, , Editor, Nobel, 2018

## Refereed Congress / Symposium Publications in Proceedings

**I. Atezolizumab in patients with metastatic urothelial carcinoma who have progressed after first-line chemotherapy: Results of real-life experience**

Tural D., Olmez O. F., Sumbul A. T., Artac M., Ozhan N., Akar E., Cakar B., Kostek O., Paksoy N., Erman M., et al.

Genitourinary Cancers Symposium of the American-Society-of-Clinical-Oncology (ASCO), San-Francisco, Costa Rica, 13 - 15 February 2020, vol.38

**II. BİR ÜNİVERSİTENİN SİGARA BIRAKMA ÜNİTESİNE BAŞVURANLARIN ÖZELLİKLERİ VE SİGARA BIRAKMA OLASILIKLARI**

ŞENGELEN M., ÇELİK İ., ERMAN M., Tezcan S., YÜCE D., KAMIŞLI S., küçükçoban ş., HAYRAN K. M.

2. ULUSLARARASI 20. ULUSAL HALK SAĞLIĞI KONGRESİ, Antalya, Turkey, 13 - 17 November 2018

**III. EFFECTS OF CANCER TYPES ON LOCAL AND OUT-OF-CITY ADMISSIONS FOR MEDICAL CARE**

HAYRAN K. M., YÜCE D., KILIÇKAP S., DİZDAR Ö., houssein b., ERMAN M., ÇELİK İ.

ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018

**IV. TRANSCULTURAL ADAPTATION OF EORTC-QLQ-CR29 SCALE INTO TURKISH, AND ASSESSMENT OF VALIDITY ANDRELIABILITY IN TURKISH PATIENTS WITH COLORECTAL CANCER**

HAYRAN K. M., YÜCE D., KILIÇKAP S., houssein b., ERMAN M., DİZDAR Ö., ÇELİK İ.

ISPOR Asia Pacific 2018, Tokyo, Japan, 8 - 11 November 2018, vol.1, pp.11

**V. İki olgu nedeniyle Nivolumumaba bağlı akciğer toksisitesi**

BABAOĞLU E., SARINÇ ULAŞLI S., KÖKSAL D., ERMAN M., BARIŞTA İ.

Ulusal Akciğer Sağlığı Kongresi, Turkey, 14 - 18 March 2018

**VI. Brain Tissue Follow-up Using Dynamic Susceptibility Contrast-Enhanced and Dynamic Contrast-Enhanced Perfusion Magnetic Resonance Imaging on Lesions Categorized by Apparent Diffusion Coefficient Values in Glioblastoma**

OMAY B., ARDALI S., MUT AŞKUN M., KILIÇKAP S., ERMAN M., KARLI OĞUZ H. K.



Radiology Society of North America, 26 November - 01 December 2017

- VII. **Efficiency of a psychoeducational Intervention for smoking cessation in a specialized cessation clinic**  
YÜCE D., KAMIŞLI S., KÜÇÜKÇOBAN Ş., HAYRAN K. M., KILIÇKAP S., ÇELİK İ., ERMAN M.  
2017 World Congress of Psycho-Oncology, 14 - 18 August 2017
- VIII. **Metastatik kastrasyona dirençli prostat kanser hastalarında kabazitakselin güvenlik verileri: Kabazitaksel Türkiye insani amaçlı ilaca erişim programı sonuçları**  
BAVBEK S., BAŞARAN M., ÖZEN A. H., ERMAN M., ÖZDOĞAN M., ÖZGÜROĞLU M., GÖKER E.  
22. ULUSAL KANSER KONGRESİ, Turkey, 19 - 23 April 2017
- IX. **Smoker relatives of inpatients: A reasonable but heterogeneous target population for smoking cessation program**  
AKTAŞ B. Y., HOUSSEİN b., YÜCE D., DİZDAR Ö., KILIÇKAP S., ERMAN M., HAYRAN K. M., ÇELİK İ.  
7th ECTOH Conference on Tobacco or Health, Porto, Portugal, 22 - 25 March 2017
- X. **Tirozin Kinaz İnhibitörü Kaynaklı Tiroid Fonksiyon Bozukluğu**  
TECEN K., ÖZDEMİR N., KARA E., EKİNCİOĞLU A., DEMİRKAN S. K., ERMAN M., KILIÇKAP S.  
18. ULUSAL İÇ HASTALIKLARI KONGRESİ, Turkey, 12 - 16 October 2016
- XI. **Using geographical information systems to describe quality of life as a function of distance in cancer patients**  
HAYRAN K. M., ERMAN M., KILIÇKAP S., DİZDAR Ö., YÜCE D., HÜSEYİN B., ÇELİK İ.  
ISPOR Asia Pacific Meeting 2016, 3 - 06 September 2016, vol.19, pp.892
- XII. **Factors that affect the suitability of cancer patients for clinical drug trials in Turkey: Final analysis of a multicenter study.**  
Erman M., Kilickap S., Ekinci A. S., Koca S., Ata A., Besen A., Can A., Dane F., Babacan T., Oksuzoglu B.  
Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer, Illinois, United States Of America, 29 May - 02 June 2015, vol.33
- XIII. **Temporal changes in the survival of metastatic renal cell cancer patients and the impact of targeted agents: Single center experience**  
Erman M., Arik Z., Kilickap S., Bilen C. Y., Yazici S., Akdogan B., Ozen H.  
Genitourinary Cancers Symposium, San-Francisco, Costa Rica, 30 January - 01 February 2014, vol.32
- XIV. **Anti TNF treatment may induce EBV reactivation in RA patients A clue for increased risk of lymphoma**  
TOKGÖZOĞLU S. L., ERTENLİ A. İ., KALYONCU U., ALP A., KARADAĞ Ö., ERMAN M., HASÇELİK A. G., APRAŞ BİLGEN Ş., AKDOĞAN A., MARAŞ Y., et al.  
Annual European Congress of Rheumatology (EULAR 2006), 21 - 24 June 2006
- XV. **Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin's lymphoma**  
Kilickap S., Yavuz B., Aksoy S., Sahiner L., Harputluoglu H., Dincer M., Erman M., Aytemir K., Tokgozoglul., Barista I.  
30th Congress of the European-Society-for-Medical-Oncology, İstanbul, Turkey, 29 September - 03 October 2006, vol.17, pp.202
- XVI. **An open study of clarithromycin in the treatment of pneumonia due to Streptococcus pneumoniae**  
HAYRAN M., Erman M., GUR D., Akova M., Unal S.  
3rd International Conference on the Macrolides, Azalides, and Streptogramins, Lisbon, Portugal, 24 - 26 January 1996, vol.21, pp.429-431

## Supported Projects

ERMAN M., Project Supported by Higher Education Institutions, Görsel Eğitsel Programla Kemoterapi Alan Hastalara Verilen Eğitimin Etkinliğinin Değerlendirilmesi, 2011 - 2018

## **Metrics**

Publication: 99

Citation (WoS): 363

Citation (Scopus): 453

H-Index (WoS): 12

H-Index (Scopus): 13

## **Non Academic Experience**

Hacettepe Üniversitesi

Hacettepe Üniversitesi

Hacettepe Üniversitesi

Hacettepe Üniversitesi

Hacettepe Üniversitesi

Hacettepe Üniversitesi